News | August 11, 2024
Aurobindo posts Q1 FY25 PAT higher by 61% at Rs. 7,567 Cr
Revenue from Operations increased by 10.5% YoY to Rs. 7,567 crore with growth across the businesses
Revenue from Operations increased by 10.5% YoY to Rs. 7,567 crore with growth across the businesses
The company reported total income at Rs. 509.8 crore in Q1 FY25 as compared to Rs. 570.3 crore in Q1 FY24
Against targeted investment of Rs. 3,938 crore, investments worth Rs. 4,024 crores have been made under scheme
The pharma market is showing encouraging signs of improvement, positioning us well for future growth
Expect the international business including CDMO business to pick-up in the second half of the financial year
He advocated for a "PPP + PPP" collaboration, urging the public and private sectors within India to partner with their counterparts in other countries
Being the first approved applicant, Lupin is eligible for 180 days of CGT exclusivity
SMS Pharmaceuticals has reported total income of Rs. 165.81 crores during the quarter ended June 30, 2024
Finerenone significantly reduced the composite of cardiovascular death and total (first and recurrent) heart failure events compared to placebo in addition to usual therapy
Dr. Vinod Kumar Paul highlighted the huge gap between the demand for and supply of organs
Subscribe To Our Newsletter & Stay Updated
